While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

No longer a mere assistant who carries out the commands of DNA, RNA takes the lead in emerging therapeutics.

After years of development, Isomorphic Labs says its AI-created drugs are nearly ready for human trials. Isomorphic Labs, the ...

The first pillar focuses on enhancing the value chain. “Ireland is well-positioned to become a key orchestrator within the ...

The development of prodrugs — chemically modified versions of pharmacologically active agents that must undergo transformationin vivoto release the active drug — is a well-established strategy ...

EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide. For more ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

His research shows molecular changes in brain cells when a person develops multiple sclerosis (MS). But it is still unclear ...

Industry Trends Published: September 1999 Cardiovascular disease drug discovery Aris Persidis Nature Biotechnology 17, 930–931 (1999) Cite this article ...

Today, Zacks Equity Research discusses The Estee Lauder Companies Inc. EL, Coty Inc. COTY and European Wax Center, Inc. EWCZ. Industry: Cosmetics ...

The company commissioned economic modelling that suggests AI could unlock $115 billion in value by 2030 if Australia gets ...